AIFA published the 2023 OsMed Report “The use of medicines in Italy”

Appropriateness, therapeutic adherence and use of equivalent medicines improved, but there is considerable room for improvement.

Poor adherence to therapies costs two billion a year, AIFA's Working Group on Precision Medicine and Prescriptomics kicks off to improve it

In addition to the Agency's experts, the Working Group is also attended by scientific Societies, organisations of health professionals and academics in the field, who are already organised into working groups that should lead to an event where the results of the research activity will be published within a year.

Biosimilar medicines in Italy: AIFA reports updated

The Agency publishes the reports on the monitoring of biosimilar drugs in Italy, updated to April 2024.

In addition to the consumption and expenditure trends and regional variability two further analyses are present on the evolution of prices in the various distribution channels (approved care regime, per conto and direct distribution) as well as on the consumption trend of intravenous and subcutaneous formulations, where available.

The aim is to provide useful information to healthcare professionals who deal with monitoring and governance of pharmaceutical expenditure, to promote the use of patent-expired medicines, assess the effectiveness of regional tenders, identify opportunities of intervention and monitor the effects of the policies put in place.

Nisticò (AIFA): "In order to speed up access to medicines, it is essential to strengthen and qualify the Agency's personnel"

“The hope is that the provisions expunged from the manoeuvre may find a place in the parliamentary conversion”.